IMCR7:00 AMImmunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanomaEnrollment • Phase 3Enrollment milestone Mon, Sep 14, 2026, 7:00 AM EDTGimmunocore.com